The metabolic reprogramming and vulnerability of SF3B1 mutations

被引：4
|
作者：
Dalton, W. Brian [1 ]
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, 1650 Orleans St,CRBI Room 285, Baltimore, MD 21231 USA
来源：
MOLECULAR & CELLULAR ONCOLOGY | 2020年 / 7卷 / 03期
关键词：
spliceosome; serine; PHGDH; metabolism;
D O I：
10.1080/23723556.2019.1697619
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Mutations in the splicing factor 3b subunit 1 (SF3B1) gene create a neomorphic protein that disrupts RNA splicing, but the downstream consequences of this missplicing are unclear. Our recent study of isogenic human cells demonstrated that SF3B1(MUT) induces reprogramming of energy metabolism and a targetable vulnerability to deprivation of the nonessential amino acid serine.
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia
    M Schwaederlé
    E Ghia
    L Z Rassenti
    M Obara
    M L Dell' Aquila
    J F Fecteau
    T J Kipps
    Leukemia, 2013, 27 : 1214 - 1217
  • [42] Understanding the Role of Mutations in SF3B1 and Splicing in Chronic Lymphocytic Leukemia
    Wu, Catherine J.
    BLOOD, 2012, 120 (21)
  • [43] Lack of SF3B1 R625 mutations in cutaneous melanoma
    Schilling, Bastian
    Bielefeld, Nicola
    Sucker, Antje
    Hillen, Uwe
    Zimmer, Lisa
    Schadendorf, Dirk
    Zeschnigk, Michael
    Griewank, Klaus G.
    DIAGNOSTIC PATHOLOGY, 2013, 8
  • [44] The impact of SF3B1 mutations in CLL on the DNA-damage response
    te Raa, G. D.
    Derks, I. A. M.
    Navrkalova, V.
    Skowronska, A.
    Moerland, P. D.
    van Laar, J.
    Oldreive, C.
    Monsuur, H.
    Trbusek, M.
    Malcikova, J.
    Loden, M.
    Geisler, C. H.
    Hullein, J.
    Jethwa, A.
    Zenz, T.
    Pospisilova, S.
    Stankovic, T.
    van Oers, M. H. J.
    Kater, A. P.
    Eldering, E.
    LEUKEMIA, 2015, 29 (05) : 1133 - 1142
  • [45] SF3B1 and SF3B3 Expression in Tamoxifen Resistance
    Gokmen-Polar, Y.
    Nellamraju, Y.
    Goswami, C. P.
    Gu, X.
    Janga, S. C.
    Badve, S.
    LABORATORY INVESTIGATION, 2014, 94 : 50A - 50A
  • [46] SF3B1 and SF3B3 Expression in Tamoxifen Resistance
    Gokmen-Polar, Y.
    Nellamraju, Y.
    Goswami, C. P.
    Gu, X.
    Janga, S. C.
    Badve, S.
    MODERN PATHOLOGY, 2014, 27 : 50A - 50A
  • [47] Impact of SF3B1 mutation in myelofibrosis
    Senapati, Jayastu
    Verstovsek, Srdan
    Masarova, Lucia
    Pemmaraju, Naveen
    Patel, Keyur P.
    Montalban-Bravo, Guillermo
    Pierce, Sherry A.
    Zhou, Lingsha
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Bose, Prithviraj
    LEUKEMIA & LYMPHOMA, 2022, 63 (11) : 2701 - 2705
  • [48] Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations
    Venable, Elise R.
    Chen, Dong
    Chen, Constance P.
    Bessonen, Kurt R.
    Nguyen, Phuong L.
    Oliveira, Jennifer L.
    Reichard, Kaaren K.
    Hoyer, James D.
    Althoff, Simon D.
    Roh, Dana J.
    Miller, Mechelle A.
    Begna, Kebede
    Patnaik, Mrinal M.
    Litzow, Mark R.
    Al-Kali, Aref
    Viswanatha, David S.
    He, Rong
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2021, 156 (04) : 679 - 690
  • [49] Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells
    X Wu
    R C Tschumper
    D F Jelinek
    Leukemia, 2013, 27 : 2264 - 2267
  • [50] SF3B1 and the riddle of the ring sideroblast
    Gattermann, Norbert
    BLOOD, 2012, 120 (16) : 3167 - 3168
12345